Cartesian Therapeutics, Inc. (RNAC)

Every figure this model derived for RNAC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,083,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 147,606,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 153,615,000 AssetsCurrent 2026-06-30
current liabilities 20,550,000 LiabilitiesCurrent 2026-06-30
equity -125,226,000 StockholdersEquity 2026-06-30
ocf -76,529,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,477,000 Revenues 2026-06-30
sbc 9,240,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RNAC on one particular measure came for.

RatioValue
current ratio7.48
current ratio reported7.48
deferred revenue growth-100.0
growth cv2.83
revenue growth43.96
revenue growth per share43.96
rule of 40-10474.59
sbc pct revenue625.59

What to be careful about

What this model itself distrusts about RNAC's figures. Written by the derivation as it ran, not added afterwards.